Factor This Power Engineering
Live Events
DTECH® Events
POWERGENâ¢
Calendar
Webinars
Podcasts
Contribute Content
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Smart Grids
Transmission
Hydropower
Dams & Civil Structures
Small Hydropower
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Project Development
Tariffs
Electric Vehicles
EV Charging
Vehicle to Grid
Subscribe
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Transmission
Smart Grids
Hydropower
Dams & Civil Structures
Small Hydro
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Electric Vehicles
EV Charging
Vehicle to Grid
Factor This: Power Engineering
Live Events
DISTRIBUTECH®
Podcasts
Webinars
Calendar
Contribute Content
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Amgen
(NQ:
AMGN
)
341.71
+4.97 (+1.48%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 17, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Amgen
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
60
61
Next >
Behind the Scenes of Amgen's Latest Options Trends
↗
March 04, 2025
Via
Benzinga
Amgen-AstraZeneca Partnered Asthma Drug Shows Rapid And Sustained Effect In Chronic Rhinosinusitis
↗
March 03, 2025
Amgen and AstraZeneca's Tezspire showed significant reductions in nasal polyp severity, congestion, and surgery need in CRSwNP patients in the Phase 3 WAYPOINT trial.
Via
Benzinga
Bitcoin, Magnificent 7 Lose Safe-Haven Status In 2025 As China ETFs, Dow Stocks Outperform
↗
February 28, 2025
Many of the top-performing stocks and assets in recent years have stumbled at the start of 2025, with Bitcoin (CRYPTO: BTC) dropping to a three-month low.
Via
Benzinga
Topics
ETFs
Stocks
This Could Be the Best GLP-1 Stock to Buy in 2025
↗
February 28, 2025
Via
The Motley Fool
Looking Into Amgen's Recent Short Interest
↗
February 19, 2025
Via
Benzinga
Amgen Unusual Options Activity For February 12
↗
February 12, 2025
Via
Benzinga
Amgen Options Trading: A Deep Dive into Market Sentiment
↗
February 05, 2025
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
↗
February 26, 2025
Via
Benzinga
These 3 Dow Jones Stocks Are Crushing It in 2025. Are They Still Buys?
↗
February 25, 2025
Via
The Motley Fool
Topics
Stocks
Synchronicity: Denying The Unexplainable
↗
February 24, 2025
Elon Musk and Neurolinks has been loud about the singularity—AI surpassing human intelligence. But has curiosity has lost its oomph?
Via
Talk Markets
Topics
Stocks / Equities
Large Cap Biopharmaceutical Metrics And Performance Q1 2025
↗
February 20, 2025
Tariffs could have big impact on earnings in 2025.
Via
Talk Markets
Topics
Stocks / Equities
10 Health Care Stocks With Whale Alerts In Today's Session
↗
February 11, 2025
Via
Benzinga
Earnings Summary: Amgen Q4
↗
February 04, 2025
Via
Benzinga
Amgen Beat Fourth-Quarter Expectations. So, Why Did Shares Tumble?
↗
February 04, 2025
In after-hours trades, Amgen stock fell around 2% following its fourth-quarter beat.
Via
Investor's Business Daily
Gilead Sciences (GILD) Q4 Earnings: What To Expect
February 10, 2025
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here’s what to expect.
Via
StockStory
Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move
↗
February 10, 2025
Via
The Motley Fool
3 Fabulous Dividend Stocks to Buy in February
↗
February 09, 2025
Via
The Motley Fool
Vertex Pharmaceuticals (VRTX) Q4 Earnings Report Preview: What To Look For
February 09, 2025
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon. Here’s what to look for.
Via
StockStory
We Asked Retail Traders About Eli Lilly’s Biggest Post-Q4 Risk — Most Say It’s The Weight-Loss Drug Wars
↗
February 07, 2025
Lilly’s fiercest competitor in the obesity market is Novo Nordisk, which offers Ozempic and Wegovy. However, rising threats from other players such as Hims & Hers, Amgen, and Viking Therapeutics also...
Via
Stocktwits
Uber To $80? Here Are 10 Top Analyst Forecasts For Thursday
↗
February 06, 2025
Via
Benzinga
What's going on in today's session: S&P500 movers
↗
February 05, 2025
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Wednesday. Discover which stocks are leading as top gainers and losers in today's session.
Via
Chartmill
Stay informed with the top movers within the S&P500 index on Wednesday.
↗
February 05, 2025
Curious about the top performers within the S&P500 index in the middle of the day on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Via
Chartmill
Why Amgen (AMGN) Stock Is Trading Up Today
February 05, 2025
Shares of biotech company Amgen (NASDAQ:AMGN) jumped 5.3% in the afternoon session after the company reported strong fourth-quarter results. Amgen exceeded analysts' revenue expectations this quarter,...
Via
StockStory
Stocks Rebound, Google Eyes Worst Drop In A Year, Gold Shatters Fresh Records: What's Driving Markets Wednesday?
↗
February 05, 2025
Wall Street rose on Wednesday, with all major equity indices advancing as investors assessed the latest batch of corporate earnings and drew optimism from positive labor market data.
Via
Benzinga
Amgen Impresses With Q4 Earnings Beat, Analysts See Growth Ahead
↗
February 05, 2025
Amgen posted Q4 sales of $9.1 billion, up 11%, surpassing forecasts. EPS beat estimates, and analysts remain optimistic about growth prospects in 2025.
Via
Benzinga
Topics
Earnings
Earnings Miss? Amgen’s Dividend Still a Bright Spot
February 05, 2025
Via
MarketBeat
Amgen (AMGN) Q4 2024 Earnings Call Transcript
↗
February 05, 2025
AMGN earnings call for the period ending December 31, 2024.
Via
The Motley Fool
Topics
Earnings
Amgen Surpasses Q4 Earnings Forecasts
↗
February 04, 2025
Amgen reported strong fourth-quarter earnings, driven by strategic acquisitions and robust product sales growth.
Via
The Motley Fool
Amgen’s (NASDAQ:AMGN) Q4 Sales Top Estimates, Full-Year Outlook Slightly Exceeds Expectations
February 04, 2025
Biotech company Amgen (NASDAQ:AMGN) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 10.9% year on year to $9.09 billion. The company’s full-year revenue guidance of...
Via
StockStory
These Were the 5 Top-Performing Stocks in the Dow Jones Industrial Average in January 2025
↗
February 04, 2025
Via
The Motley Fool
Topics
Stocks
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
60
61
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
